Memory Pharmaceuticals news from FierceBiotech
NewsRoche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
| Press ReleasesPRESS RELEASE: Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease MONTVALE, N.J., Nov. 2 -- Memory Pharmaceuticals Corp. today announced positive top-line data from the Read more... PRESS RELEASE: Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease - Statistically Significant Improvement on Primary and Secondary Endpoints - MONTVALE, N.J., Nov. 2 -- Read more... PRESS RELEASE: Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease MONTVALE, N.J., Oct. 15 -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced top-line data Read more... |
Get more Memory Pharmaceuticals coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets